NTBLQ (Notable Labs) EBITDA Margin %: -265,800.00% (As of Jun. 2024)


What is Notable Labs EBITDA Margin %?

Notable Labs NTBLQ -90.00% EBITDA Margin % is -265,800.00% as of Jun. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Notable Labs's EBITDA for the three months ended in Jun. 2024 was $-5.32 Mil. Notable Labs's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Notable Labs's EBITDA margin for the quarter that ended in Jun. 2024 was -265,800.00%.

Notable Labs  (OTCPK:NTBLQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Notable Labs EBITDA Margin % Related Terms

Notable Labs EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Notable Labs's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs EBITDA Margin % Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
EBITDA Margin %
-5,820.35 -157,512.50 -4,645.16

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
EBITDA Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 -377,500.00 -265,800.00

NTBLQ vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Notable Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Notable Labs EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Notable Labs's EBITDA Margin % falls into.


Notable Labs EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Notable Labs's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-14.4/0.31
=-4,645.16 %

Notable Labs's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-5.316/0.002
=-265,800.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -265,800.00% mean?
Notable Labs (NTBLQ) has a EBITDA Margin % of -265,800.00% as of Jun. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Notable Labs and its competitors.
Is Notable Labs' EBITDA Margin % too high?
Notable Labs' current EBITDA Margin % is -265,800.00%.
How does Notable Labs' EBITDA Margin % compare to VRTX and REGN?
Notable Labs' EBITDA Margin % of -265,800.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Notable Labs and its competitors. Notable Labs's current EBITDA Margin % is -265,800.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Notable Labs stock overvalued right now?
Notable Labs (NTBLQ) has a current EBITDA Margin % of -265,800.00%. The current EBITDA Margin % is -265,800.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Notable Labs (NTBLQ), the current EBITDA Margin % is -265,800.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Notable Labs Business Description

Address 320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.